Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Akriti Seth

Senior Reporter

London, UK
As a correspondent for Channel NewsAsia, Singapore and for India Technology News, Akriti has covered a wide range of subject-matter including politics, economics and technology for a B2B audience. She has also gained experience working for Bloomberg TV India and Mid-Day Mumbai. Akriti is a graduate of the University of Mumbai and holds a masters from Mumbai's Xavier Institute of Communications. Most recently she has worked as a freelance journalist in London, where she is now based, having lived there for the past two years. She enjoys photography and blogging.
Set Alert for Articles By Akriti Seth

Latest From Akriti Seth

Krka Introduces Cardiovascular Range To New Eastern European Markets

Reporting double-digit growth in the first half of 2019, Krka says it has mined marketing opportunities in new eastern European markets by introducing its established treatments for cardiovascular diseases

Approvals Cardiovascular

Endo Sees Strong Prospects For Hybrid Injectables Pipeline

Endo has high hope for its pipeline of 505(b)(2) hospital and critical-care drugs in the US as the group looks to return to revenue growth.

Value-Added Medicines Business Strategies

Akorn Sees A $10m Increase In FDA Compliance Expenditure

Akorn’s second-quarter results show a drop in sales despite the launch of three new products. The company expects a $10m increase in FDA compliance and data-integrity assessment expenditures because of a warning letter issued over its Somerset manufacturing facility.

Compliance Strategy

Pooled Data Among AAM’s Concerns On FDA’s Therapeutic Protein Biosimilars Guidance

Three key areas for improvement in in the FDA’s draft guidance on therapeutic protein biosimilars have been highlighted by industry association AAM. Pharmaceutical giants such as Pfizer, Novartis and Celltrion have also expressed concerns highlight shortcomings and sought clarification.

Biosimilars Regulation

Teva Strikes Two Settlements Over ‘Pay-For-Delay’ Agreements

A California Court has secured four major settlements worth $70m with pharmaceutical companies over allegations of entering into collusive pay-for-delay agreements, including two with Teva.

Deals Generic Drugs

Bipartisan US Senate Proposal Aims To Save Medicare $85bn

A bipartisan US bill called the Prescription Drug Pricing Reduction Act 2019 aimed at lowering the price of prescription drugs for Americans has passed through the Senate finance committee. The AAM called the legislation “a step in the right direction.”

United States Pricing Strategies
See All